Zai Lab
Jing Yang currently serves as the Senior Director of Financial Reporting and US Accounting Operations at Zai Lab, overseeing SEC reporting, Hong Kong reporting, and Technical Accounting. With extensive experience in SEC compliance and financial reporting, Jing previously held roles including SEC Reporting Manager at ALX Oncology, where responsibilities included developing SEC Reporting and Technical Accounting functions, and Manager of External Reporting and Technical Accounting at Informatica, focusing on GAAP compliance and leading financial statement reviews. Prior experience as an External Auditor at EY involved auditing Fortune 500 clients, ensuring financial statement accuracy, and assessing internal controls for Sarbanes-Oxley compliance. Jing holds an integrated Master's of Accountancy and a Bachelor's Degree in Accounting from the University of Wisconsin-Madison.
This person is not in any teams
This person is not in any offices
Zai Lab
5 followers
Zai Lab Ltd is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.